Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
As of today, Neurocrine(NBIX) shares are valued at $146.85. The company's market cap stands at 14.63B, with a P/E ratio of 35.18.
During the trading session on 2025-11-13, Neurocrine(NBIX) shares reached a daily high of $148.04 and a low of $145.41. At a current price of $146.85, the stock is +1.0% higher than the low and still -0.8% under the high.
Trading volume for Neurocrine(NBIX) stock has reached 1.14M, versus its average volume of 1.25M.
The stock's 52-week range extends from a low of $84.23 to a high of $157.67.
The stock's 52-week range extends from a low of $84.23 to a high of $157.67.
NBIX News
Neurocrine Biosciences (NBIX) just shared results from a Phase 2 study of its experimental treatment for major depressive disorder. The results revealed the com...
On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary en...
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional...
Analyst ratings
90%
of 30 ratingsMore NBIX News
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Neurocrine (NBIX) to $173 from $178 and keeps an Overweight rating on the shares after the...
Neurocrine Biosciences reported third quarter 2025 earnings, showing revenue of US$794.9 million and net income of US$209.5 million, both up from the same perio...